NICE recommends Vir's sotrovimab for COVID-19 in UK; no meaningful 2023 sales expected

Vir Biotechnology, Inc.

NICE final draft guidance recommends sotrovimab for high-risk adults where Paxlovid is contraindicated or unsuitable.
Recommendation based on cost-effectiveness evaluation of sotrovimab.
No meaningful additional UK sales of sotrovimab anticipated in 2023 due to existing inventory.
Sotrovimab (Xevudy) authorized in over 40 countries; not authorized in the US.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.